1437P Tislelizumab (TIS) + chemotherapy (CT) vs placebo (PBO) + CT in HER2-negative advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma (GC/GEJC): RATIONALE-305 study minimum 3-year survival follow-up
| Autor: | Cruz-Correa, M., Oh, D-Y., Kato, K., Tabernero, J., Bai, Y., Shi, J., Lee, K-W., Hirano, H., Spigel, D.R., Wyrwicz, L.S., Pazo Cid, R.A., Cubillo Gracian, A., Li, L., Xu, Y., Sheng, T., Yang, S., Xu, R-H., Moehler, M. |
|---|---|
| Zdroj: | In Annals of Oncology September 2024 35 Supplement 2:S893-S894 |
| Databáze: | ScienceDirect |
| Externí odkaz: |
|